



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Fetuin A and abdominal aorta calcification in hemodialysis patients

Thesis

Submitted by

Mohammed Abdel Halim Askar

M.B.B.Ch

Faculty of medicine
Mansoura University

Supervised by

Dr. Osama Mahmoud Kamal

Professor of Internal medicine and Nephrology
Faculty of Medicine
Ain Shams University

Dr. Tamer Waheed Elsaed

Ass. Professor of Internal medicine and Nephrology
Faculty of Medicine
Ain Shams University

Dr. Ashraf Hassan Abdel mobdy

lecturer of Internal medicine and Nephrology
Faculty of Medicine
Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First of all ,thanks to **allah** the most merciful and the most beneficial ,who gave me the will to start ,the power to continue and the goal to reach .*

*I wish to express my deepest thanks ,unlimited dept.of gratitude, sincere respect and grateful acknowledgment to **prof. Dr Osama Mahmoud Kamal** professor of internal medicine and nephrology , faculty of medicine , Ain shams university ,for his great help in choosing the topic and the tools of the thesis, his remark and scientific advice and encouragment , to him I will always be thankful .*

*Words cannot express my feelings of gratitude and respect to **Ass.Prof.Dr. Tamer waheed elsaeed** Ass .Professor of Internal medicine and Nephrology , Faculty of Medicine ,Ain Shams University & **Dr. Ashraf Hassan Abdel mobdy** , lecturer of Internal medicine and Nephrology , Faculty of Medicine ,Ain Shams University for their kind support and advice .*

*Finally , I wish to express my great thanks and gratitude to **my family** for their help and support .*

List of Contents

❖ Introduction	page ١
❖ Aim of the work	page ٤
❖ <u>Review of literature</u>	
* chapter 1 : Hemodialysis complications	page ٥
* chapter 2 : Bone kidney disease	page ١٥
* chapter 3 : Calciphylaxis	page ٣٧
* chapter 4 : Fetuin A	page ٧١
* chapter 5: Imaging of calciphylaxis	page ٨٦
❖ Patients and methods :	page ٩٧
❖ Results :	page ١٠٩
❖ Discussion :	page ١٣٨
❖ Summary	page ١٦٠
❖ Conclusion	page ١٦٣
❖ Limitation	page ١٦٤
❖ Arabic summary :	page ١٦٥
❖ References :	page ١٧٥

LIST OF TABLES

number	Description	Page
Table (1)	Stages of chronic kidney diseases.	5
Table (2)	Cardiovascular diseases risk factors in hemodialysis patients.	9
Table (3)	Different types of cardio-renal syndromes.	10
Table (4)	Guidlines for management of anemia in CKD.	12
Table (5)	Causes of vitamin D defeciency in chronic kidney disease.	20
Table (6)	Frequency of measurment of serum Ca , po4 and PTH.	22
Table (7)	Spectrum of bone mineral diseases in CKD.	25
Table (8)	Indication of bone biobsy in BMD-CKD.	25
Table (9)	Principle histo-morphometric parameters in BMD-CKD.	26
Table (10)	Goal therapy in BMD-CKD.	26
Table (11)	Criteria of ideal phosphate binder.	28
Table (12)	Summary of phosphate binders.	30
Table (13)	Indication of parathyroidectomy in BMD-CKD.	34
Table (14)	Contraindications of parathyroidectomy in BMD-CKD.	35
Table (15)	Prevalence of calciphylaxis.	36
Table (16)	Risk factors of calciphylaxis .	38
Table (17)	Types of vascular calcifications.	43
Table (18)	Promotors and inhibitors of vascular calcification .	44
Table (19)	Differential diagnosis of calciphylaxis.	61
Table (20)	Role of vitamin D in mangment of calciphylaxis .	64
Table (21)	Phosphate binders used in calciphylaxis .	65
Table (22)	Functional properties of fetuin A.	72
Results		
Table (23)	Comparison between the studied groups regarding age (year) .	108
Table (24)	Comparison between the studied groups regarding sex .	109
Table (25)	Comparison between the studied groups regarding smoking and history of previous fracture.	110
Table (26)	Comparison between the studied groups regarding duration of dialysis (month) .	111
Table (27)	Comparison between the studied groups regarding body mass index (Kg/m2) .	112
Table (28)	Comparison between the studied groups regarding the etiology of chronic kidney disease .	113
Table (29)	Comparison between the studied groups regarding the usage of anti hypertensive and anti diabetic drugs .	114

Table (30)	Comparison between the studied groups regarding drugs affecting calcium , phosphate , PTH and vitamin D axis .	115
Table (31)	Comparison between the studied groups regarding the usage of statins and aspirin therapy .	116
Table (32)	Comparison between the studied groups regarding measured Fetuin A (ng/ml) .	117
Table (33)	Comparison between the studied groups regarding measured serum calcium (mg/dl) and corrected serum calcium(mg/dl) .	118
Table (34)	Comparison between the studied groups regarding measured serum albumin (g/dl) and serum phosphorus (mg/dl) .	119
Table (35)	Comparison between the studied groups regarding Calcium phpsphorus product (mg ² /dl ²).	120
Table (36)	Comparison between the studied groups regarding measured serum PTH (mg/dl) .	121
Table (37)	Comparison between the studied groups regarding measured vitamin D (Pg/ml) .	122
Table (38)	Recevier operating characteristic (RCO) curve between group (A) and group (B) regarding fetuin A plasma level .	123
Table (39)	Correlation between fetuin A and age in the studied groups .	124
Table (40)	Correlation between fetuin A and duration of dialysis in the studied groups .	125
Table (41)	Correlation between fetuin A and body mass index in the studied groups .	126
Table (42)	Correlation between fetuin A and serum calcium in the studied groups .	127
Table (43)	Correlation between fetuin A and serum albumin in the studied groups .	128
Table (44)	Correlation between fetuin A and corrected calcium in the studied groups .	129
Table (45)	Correlation between fetuin A and serum phosphorus in the studied groups .	130
Table (46)	Correlation between fetuin A and calcium phosphorus product in the studied groups .	131
Table (47)	Correlation between fetuin A and PTH in the studied groups .	132
Table (48)	Correlation between fetuin A and vitamin D in the studied groups .	133
Table (49)	Correlation between fetuin A and aortic calcium score in the studied groups .	134
Table (50)	Correlation between fetuin A and age, smoking , history of previous fracture in the studied groups	134
Table (51)	Correlation between fetuin A and etiology of CKD in the studied groups	135
Table (52)	Correlation between fetuin A and drug history in the studied groups	136

LIST OF FIGURES

Number	Description	Page
Figure (1)	Causes of chronic kidney diseases.	7
Figure (2)	Chronic kidney diseases complications.	8
Figure (3)	Spectrum of renal bone diseases .	17
Figure (4)	Spectrum of bone histology in BMD-CKD.	18
Figure (5)	Pathogenesis of renal bone diseases.	20
Figure (6)	Subperiosteal resorption of bone of middle and terminal phalanges .	23
Figure(7)	Mechanism of action of calcimimetics .	32
Figure (8)	Anatomy of parathyroid glands .	33
Figure (9)	Risk factors of calciphylaxis.	37
Figure (10)	Pathogenesis of calciphylaxis .	39
Figure (11)	molecular mechanisms controlling calciphylaxis	39
Figure (12)	Types of vascular calcification	43
Figure (13)	Promoters and inhibitors of vascular calcifications	45
Figure (14)	Role of hyperphosphatemia and calcium phosphorus product in development of calciphylaxis.	54
Figure (15)	Approach to diagnosis and management of calciphylaxis .	68
Figure(16)	Molecular structure of fetuin A as seen by electron microscope	70
Figure(17)	protective role of Fetuin A in peripheral ischemic injury and sepsis .	74
Figure (18)	Role of fetuin A in insulin resistance and metabolic syndrome.	77
Figure (19)	Role of fetuin A in inhibition of vascular calcification.	82
Figure (20)	Plain X-ray of hand and wrist showing radial artery calcification	84
Figure (21)	Plain X- ray of right foot showing calcification of calcaneal planter artery.	85
Figure (22)	Ultrasound showing common carotid artery calcification	86
Figure (23)	Lateral dual-energy X-ray absorptio metric image showing aortic calcification.	89
Figure (24)	CT scan of abdomen showing descending aorta calcification , calcification of renal and mesenteric blood vessels .	91
Results		
Figure (25)	Comparison between the studied groups regarding age .	108
Figure (26)	Comparison between the studied groups regarding sex .	109
Figure (27)	Comparison between the studied groups regarding smoking and history of previous fracture.	110

Figure (28)	Comparison between the studied groups regarding duration of dialysis (month) .	111
Figure (29)	Comparison between the studied groups regarding body mass index (Kg/m ²) .	112
Figure (30)	Comparison between the studied groups regarding the etiology of chronic kidney disease	113
Figure(31)	Comparison between the studied groups regarding the usage of anti hypertensive and anti diabetic drugs .	114
Figure (32)	Comparison between the studied groups regarding drugs affecting calcium , phosphate , PTH and vitamin D axis .	115
Figure (33)	Comparison between the studied group regarding the usage of statins and aspirin therapy .	116
Figure (34)	Comparison between the studied groups regarding measured Fetuin A (ng/ml) .	117
Figure (35)	Comparison between the studied groups regarding measured serum calcium (mg/dl) and corrected serum calcium(mg/dl) .	118
Figure (36)	Comparison between the studied groups regarding measured serum albumin (g/dl) and serum phosphorus (mg/dl) .	119
Figure (37)	Comparison between the studied groups regarding Calcium phpsphorus product (mg ² /dl ²).	120
Figure (38)	Comparison between the studied groups regarding measured serum PTH (mg/dl) .	121
Figure (39)	Comparison between the studied groups regarding measured vitamin D (Pg/ml) .	122
Figure (40)	Recevier operating characteristic (RCO) curve between group (A) and group (B) regarding fetuin A plasma level .	123
Figure (41)	Correlation between fetuin A and age in the studied groups .	124
Figure (42)	Correlation between fetuin A and duration of dialysis in the studied groups .	125
Figure (43)	Correlation between fetuin A and body mass index in the studied groups .	126
Figure (44)	Correlation between fetuin A and serum calcium in the studied groups .	127
Figure (45)	Correlation between fetuin A and serum albumin in the studied groups .	128
Figure (46)	Correlation between fetuin A and corrected calcium in the studied groups .	129
Figure (47)	Correlation between fetuin A and serum phosphorus in the studied groups .	130
Figure (48)	Correlation between fetuin A and calcium phosphorus product in the studied groups .	131
Figure (49)	Correlation between fetuin A and PTH in the studied groups .	132

List of abbreviations

abbreviati	Meaning
A	
AAC	Abominal aortic calcification
AAKP	American Association of Kidney Patients
ABPI	rachial bracial index pressure
ACEIs	Angiotensin converting enzyme inhibitors
AIDS	acquired immunodeficiency syndrome
AHSG	Alpha 2 heremans schmid glycoprotein
ACR	Albumin creatinine ratio
AF	fbrillation atrial
AKI	Acute kidney injury
ALP	Alkaline phosphatase
ANAC	Anti neutrophil cytoplasmic antibodies
AOAC	Aortic arch calcification
APD	automated peritoneal dialysis
APLS	Antiphosholipid syndrome
APP	Acute phase protein
ASO	Antistreptolysin o
ARBs	Angiotensin receptor blockers
AVF	arteriovenous fistula
AVG	arteriovenous graft
B	
BBB	Blood brain barrier
BFR	blood flow rate
Bp	Blood pressure
BMI	body mass index
BMP	morphogenetic protein bone
BNP	BrainNatriureticPeptide
BSA	body surface area
BUN	blood urea nitrogen
BX	biobsy
BMD	Bone mineral density
C	
Ca	Calcium
CACS	Coronary artery calcification score
CAD	Coronary artery disease
CARP	Calcification regulatory proteins
CaSR	Calcium sensing receptor
CXR	Chest X ray
CBFA1	Core binding factor alpha 1
CNS	Central nervous system
CRP	C reactive protein
CA II	carbonic anhydrase isoenzyme II

CAC	Coronary artery calcium
CAD	coronary artery disease
CAPD	continuous ambulatory peritoneal dialysis
CCB	Calcium channel blocker
CCP	Circulating calciprotein particles
CrCl	Creatinine clearance
CFU	Colony forming unit
CHF	congestive heart failure
CFU	colony -forming unit
CKD	Chronic kidney disease
CKD-	Chronic kidney disease- mineral bone disease
CPP	Calciprotein particle
CrCl	Creatinine clearance
CRF	Chronic renal failure
CRP	C reactive peptide
CUA	Calcific uremic arteriopathy
<i>D</i>	
DEXA	Dual energy X ray absorptiometry
DIC	Disminnated intravascular coagulation
DM	diabetes mellitus
DVT	Deep venous thrombosis
<i>E</i>	
EBCT	Electron beam computed tomography
ECG	Electrocardiograph
ECF	extra cellular fluid
EIPD	extended intermittent peritoneal dialysis
ELIZA	Enzyme Linked ImmunoSorbent Assay
ENPP	ecto-nucleotide pyrophosphatase
ERA-	EuropeanRenalAssociation-
ESR	erythrocyte sedimentation rate
ESRD	End stage renal disease
ESRF	End Stage Renal Failure
ESA	Erythropioesis stimulating agents
EPO	Erythropiotin
<i>F</i>	
FGF	Fibroblast growth factor
FMC	Fetuin mineral complex
FSGS	focal segmental glomerulosclerosis
<i>G</i>	
GAS	Growth Arrest Specific Gene
GFR	glomerular filtration rate
GGC	Gamma glutamyl carboxyalase
GN	glomerulonephritis
<i>H</i>	
HD	Hemodialysis
HDL	High density lipoprotein
HITT	Heparin induced thrombocytopenia
HMGB1	High mobility group box 1 protein
HR	Hazard ratio

HS	Heremens schmid
HTN	hypertension
<i>I</i>	
IGFIR	Insulin like Growth Factor 1 receptor
IL	Interleukin
IM	Intra muscular
IRSP	Insulin receptor substrate proteins
IV	Intra venous
<i>J</i>	
<i>K</i>	
K	Potassium
KDOQI	Kidney disease outcome quality excellence
KDIGO	Kidny disease improving global outcomes
KUB	Kidney, ureter ,bladder
<i>L</i>	
LDH	Lactate dehydrogenase
LDL	low density lipoproteins
LVEF	Left Ventricular Ejection Fraction
LVH	Left ventricular hypertrophy
LVMI	Left Ventricular Mass Index
<i>M</i>	
MAC	Medial arterial calcification
MARCO	Macrophage receptor with collagenase structure
MetS	Metabolic syndrome
MGP	Matrix Gla Protein
MIA	Malnutrition - inflammation- atherosclerosis
MMP	Matrix Metalloproteinase
MRI	Magnetic resonance imaging
mRNA	Messenger Ribo Nucleic Acid
MSCT	Multi slice computed tomography
MW	molecular weight
<i>N</i>	
Na	sodium
NAFLD	Non alcoholic fatty liver disease
NCP	Non collagenous proteins
NICE	National Institute for Health and Clinical
NIDDM	non-insulin dependent diabetes mellitus
NKF	National Kidney Foundation
NLRP3	NOD like receptor 3
NO	Nitric Oxide
NSAID	Non steroidal anti inflammatory drug
<i>O</i>	
OPG	Osteoprotegerin
OPN	Osteopontin
OR	Odds Ratio
<i>P</i>	
PAD	Peripheral arterial disease